Antibody Drug Conjugates Market was valued at USD 2.51 Bn in 2021 is estimated to reach US$ 6.72 Bn in 2029, growing at a CAGR of 13.11 during the forecasted period.Antibody Drug Conjugates Market Definition:
Antibody-drug conjugates (ADC) are a highly potent biopharmaceutical drug composed of a monoclonal antibody allied to a biologically active cytotoxic or anticancer drug used as targeted therapy for cancer treatment. This ADC binds to specific antigens found in cancerous cells release its cell-killing drugs without harming other cells. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.To know about the Research Methodology :- Request Free Sample Report
Antibody Drug Conjugates Market Dynamics:
The report estimates the growth rate of Antibody Drug Conjugates Market and offers in-depth insights on market dynamics, drivers, restraints, challenges and threats till 2029. The complete information is based on the latest industry news, opportunities, and trends. The ADC therapeutics market to grow at a productive rate replicating by the introduction of new combination therapies, innovative ADC development, and advancement in medical technology. Also, wide applications and therapeutic potential beyond oncology with an increase in the number of patents are substantially driving the market growth. Moreover, more than 200 preclinical /clinical stages of development and research on advance drug discoveries, the market gradually shifted from conventional technologies to conjugated approaches. Furthermore, biopharmaceutical and Biotechnology companies are also fueling the market and expected to drive the market over the forecast of 2022-2029. However, stringent regulation set by the government for approval and different complication related with drug development besides, not so uniform growth in infrastructure across the region becomes a challenging factor for developing countries and the shortage of skilled IT specialists in healthcare are anticipating to restraints the market growth.Antibody Drug Conjugates Market: Market Segment Analysis:
The report covers the brief analytical segments of the Antibody Drug Conjugates Market thereby providing a wider view at the macro as well as micro levels. Based on application, Breast cancer is anticipated to have the largest revenue during the forecast period. Breast cancer is the most common in women and as estimated it causes half of the million death globally because of high prevalence of Breast cancer. Likewise, various procedures came into play for Breast cancer treatment. Such as ADCs and chemotherapy of which is used mainly for targeted therapy. The first ADC was Ado-Trastuzumab emtansine (T-DM1) approved by the US Food and Drug Administration for HER2-positive Breast cancer treatment and is rapidly progressing. The market is further segmented into ovarian cancer, lung cancer, blood cancer, and Breast cancer and brain tumor. In terms of type, Monoclonal antibodies is estimated to reach approximately US$ 59110 Mn by 2029 at a CAGR of 35.7%. Monoclonal antibody usually developed to target the antigen and its products are largest approved as indicator for cancers treatment, administered by injection and is highly sensitive, Monoclonal antibodies also use for immunotherapy as they help to generate the immune system against cancer.Antibody Drug Conjugates Market Regional Insights
Geographically, North America is accounted for the largest market in Antibody Drug Conjugates Market and is expected to to reach US$ 6.72Bn by 2029, with a CAGR of xx% during the forecast period. The US is estimated to have a major market among other countries such as Canada, Mexico and others. This is attributed because of the contribution of nanotechnology, presence of well-developed Biopharmaceutical companies and government initiatives in investment on R&D followed by an increasing number of product approvals and commercialization of ADCs in this sector, Likewise, the U.S. Food and Drug Administration (FDA) is one of the first regulatory affairs to approve ADCs in U.S. Hence, these factors fuel the market growth over the forecast period. Europe is the second-largest followed by Asia pacific. APAC emerged to be the fastest-growing market in ADC market because of growing economies like, India and china, promising government initiatives and growing awareness with an increasing number of biopharmaceuticals companies in APAC region probably to subsidize to the growth at the highest CAGR of 13.11% during the forecast period.Antibody Drug Conjugates Market Competitive Analysis:
The competitive landscape section in the Antibody Drug Conjugates Market highly fragmented and the offers various strategies such as agreements, new product launches, partnerships expansions, acquisitions, joint ventures, and other crucial aspects to lessen the competitive in the market. • Gemtuzumab marketed by Pfizer Inc., was the first FDA approved ADC in 2000 for the treatment of relapsed acute myeloid leukemia. • In April 2019, AbbVie proclaiming the acquisition of Stemcentrx including rovalpituzumab tesirine (Rova-T) for $5.8bn and dominated the news Furthermore, AbbVie joint venture with CytomX to develop a commercialize probody-drug conjugate (PDC) against CD71. • Regeneron Pharmaceuticals and MedImmune came into acquisition in which Regeneron will use MedImmune’s to develop ADCs against a number of cancer targets. • Adcetris (brentuximab vedotin) was approved in 2011 for relapsed Hodgkin lymphoma and relapsed anaplastic large-cell lymphoma • Moreover, in January 2018, to accelerate the growth in the cancer segment, F. Hoffmann La Roche Ltd collaborated with Syapse. The objective of the report is to present a comprehensive analysis of the Global Antibody Drug Conjugates Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market has been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers.Antibody Drug Conjugates Market Recent industry developments:
• Advancements in pharmacogenomics, Pharmacogenomics has the largest market share (24%) followed by genomics. contributes to maintaining the efficacy of a drug with the help of genetic evidence of persons. The genomics market is also predictable to grow at the highest CAGR of 13.67% during 2022–2029. • Furthermore, growing biopharmaceutical players to treat disease disorder like, cancer will drive the market growth positively. The report also helps in understanding Global Antibody Drug Conjugates Market dynamics, structure by analyzing the market segments and projects the Global Antibody Drug Conjugates Market size. Clear representation of competitive analysis of key players By Technology Type, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Antibody Drug Conjugates Market make the report investor’s guideAntibody Drug Conjugates Market Scope: Inquire before buying
Global Antibody Drug Conjugates Market Report Coverage Details Base Year: 2021 Forecast Period: 2022-2029 Historical Data: 2017 to 2021 Market Size in 2021: US $ 2.51 Bn. Forecast Period 2022 to 2029 CAGR: 13.11% Market Size in 2029: US $ 6.72 Bn. Segments Covered: by Application • Blood Cancer • Prostate cancer • kidney cancer • Pancreas cancer • Ovary cancer • Glioblastoma • lung cancer • Colon cancer • Breast cancer • Skin cancer • Solid tumors • Other cancers by Type • Monoclonal antibodies • linker • Drug/toxin • Others by product • Adcertis • Kadcyla • others by technology •ImmunoGen technology • Seattle Genetics technology • Immunomedics technology • others by end-user • Hospitals • Specialized cancer centers • Academic research institutes • Biotechnology companies • Biopharmaceutical companies • others Antibody Drug Conjugates Market, by Region
• North America • Europe • Asia Pacific • Middle East and Africa • Latin AmericaAntibody Drug Conjugates Market, key Players
• Novartis • Merck • Roche • AbbVie • UCB • Bristol-Myers Squibb • Stem CentRx • Biogen Idec • Nordic Nanovector • Millennium • Biotest AG • PDL BioPharma • Progenics Pharmaceuticals • Seattle Genetics • Viventia Biotechnologies • AbGenomics Corporation • Helix BioPharma • ImmunoGen, Inc • Synthon Holding B.V. • Sanofi S.A. • Pfizer Inc. • Immunomedics Inc. • Bayer Healthcare Pharmaceuticals • Celldex Therapeutics Inc Frequently Asked Questions: 1. Which region has the largest share in Global Antibody Drug Conjugates Market? Ans: North America region holds the highest share in 2021. 2. What is the growth rate of Global Antibody Drug Conjugates Market? Ans: The Global Antibody Drug Conjugates Market is growing at a CAGR of 13.11% during forecasting period 2022-2029. 3. What is scope of the Global Antibody Drug Conjugates market report? Ans: Global Antibody Drug Conjugates Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Antibody Drug Conjugates market? Ans: The important key players in the Global Antibody Drug Conjugates Market are – Novartis,Merck,Roche,AbbVie,UCB,Bristol-Myers Squibb,Stem CentRx,Biogen Idec,Nordic Nanovector,Millennium,Biotest AG,PDL BioPharma,Progenics Pharmaceuticals,Seattle Genetics,Viventia Biotechnologies,AbGenomics Corporation,Helix BioPharma,ImmunoGen, Inc,Synthon Holding B.V.,Sanofi S.A.,Pfizer Inc.,Immunomedics Inc.,Bayer Healthcare Pharmaceuticals,Celldex Therapeutics Inc 5. What is the study period of this market? Ans: The Global Antibody Drug Conjugates Market is studied from 2021 to 2029.
Global Antibody Drug Conjugates Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Antibody Drug Conjugates Market size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Antibody Drug Conjugates Market Analysis and Forecast 6.1. Antibody Drug Conjugates Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Antibody Drug Conjugates Market Analysis and Forecast, By Product types 7.1. Introduction and Definition 7.2. Key Findings 7.3. Antibody Drug Conjugates Market Value Share Analysis, By Product types 7.4. Antibody Drug Conjugates Market Size (US$ Bn) Forecast, By Product types 7.5. Antibody Drug Conjugates Market Analysis, By Product types 7.6. Antibody Drug Conjugates Market Attractiveness Analysis, By Product types 8. Global Antibody Drug Conjugates Market Analysis and Forecast, By Technology Type 8.1. Introduction and Definition 8.2. Key Findings 8.3. Antibody Drug Conjugates Market Value Share Analysis, By Technology Type 8.4. Antibody Drug Conjugates Market Size (US$ Bn) Forecast, By Technology Type 8.5. Antibody Drug Conjugates Market Analysis, By Technology Type 8.6. Antibody Drug Conjugates Market Attractiveness Analysis, By Technology Type 9. Global Antibody Drug Conjugates Market Analysis and Forecast, By Type 9.1. Introduction and Definition 9.2. Key Findings 9.3. Antibody Drug Conjugates Market Value Share Analysis, By Type 9.4. Antibody Drug Conjugates Market Size (US$ Bn) Forecast, By Type 9.5. Antibody Drug Conjugates Market Analysis, By Type 9.6. Antibody Drug Conjugates Market Attractiveness Analysis, By Type 10. Global Antibody Drug Conjugates Market Analysis and Forecast, By Application Type 10.1. Introduction and Definition 10.2. Key Findings 10.3. Antibody Drug Conjugates Market Value Share Analysis, By Application Type 10.4. Antibody Drug Conjugates Market Size (US$ Bn) Forecast, By Application Type 10.5. Antibody Drug Conjugates MarketAnalysis By Application Type 10.6. Antibody Drug Conjugates Market Attractiveness Analysis, By Application Type 11. Global Antibody Drug Conjugates Market Analysis and Forecast, By End User 11.1. Introduction and Definition 11.2. Key Findings 11.3. Antibody Drug Conjugates Market Value Share Analysis, By End User 11.4. Antibody Drug Conjugates Market Size (US$ Bn) Forecast, By End User 11.5. Antibody Drug Conjugates MarketAnalysis By End User 11.6. Antibody Drug Conjugates Market Attractiveness Analysis, By End User 12. Global Antibody Drug Conjugates Market Analysis, by Region 12.1. Antibody Drug Conjugates Market Value Share Analysis, by Region 12.2. Antibody Drug Conjugates Market Size (US$ Bn) Forecast, by Region 12.3. Antibody Drug Conjugates Market Attractiveness Analysis, by Region 13. North America Antibody Drug Conjugates Market Analysis 13.1. Key Findings 13.2. North America Antibody Drug Conjugates Market Overview 13.3. North America Antibody Drug Conjugates Market Value Share Analysis, By Product types 13.4. North America Antibody Drug Conjugates Market Forecast, By Product types 13.4.1. Adcertis 13.4.2. Kadcyla 13.4.3. others 13.5. North America Antibody Drug Conjugates Market Value Share Analysis, By Technology type 13.6. North America Antibody Drug Conjugates Market Forecast, By Technology Type 13.6.1. ImmunoGen technology 13.6.2. Seattle Genetics technology 13.6.3. Immunomedics technology 13.6.4. others 13.7. North America Antibody Drug Conjugates Market Value Share Analysis, By Type 13.8. North America Antibody Drug Conjugates Market Forecast, By Type 13.8.1. Monoclonal antibodies 13.8.2. linker 13.8.3. drug/toxin 13.8.4. others 13.9. North America Antibody Drug Conjugates Market Value Share Analysis, By Application Type 13.10. North America Antibody Drug Conjugates Market Forecast, By Application Type 13.10.1. Blood Cancer 13.10.2. Prostate cancer 13.10.3. kidney cancer 13.10.4. Pancreas cancer 13.10.5. Ovary cancer 13.10.6. lung cancer 13.10.7. Colon cancer 13.10.8. Breast cancer 13.10.9. Skin cancer 13.10.10. Other cancers 13.11. North America Antibody Drug Conjugates Market Value Share Analysis, By End User 13.12. North America Antibody Drug Conjugates Market Forecast, By End User 13.12.1. Hospitals 13.12.2. Specialized cancer centers 13.12.3. Academic research institutes 13.12.4. Biotechnology companies 13.12.5. Biopharmaceutical companies 13.12.6. others 13.13. North America Antibody Drug Conjugates Market Value Share Analysis, by Country 13.14. North America Antibody Drug Conjugates Market Forecast, by Country 13.14.1. U.S. 13.14.2. Canada 13.15. North America Antibody Drug Conjugates Market Analysis, by Country 13.16. U.S. Antibody Drug Conjugates Market Forecast, By Product types 13.16.1. Adcertis 13.16.2. Kadcyla 13.16.3. others 13.17. U.S. Antibody Drug Conjugates Market Forecast, By Technology Type 13.17.1. ImmunoGen technology 13.17.2. Seattle Genetics technology 13.17.3. Immunomedics technology 13.17.4. others 13.18. U.S. Antibody Drug Conjugates Market Forecast, By Type 13.18.1. Monoclonal antibodies 13.18.2. linker 13.18.3. drug/toxin 13.18.4. others 13.19. U.S. Antibody Drug Conjugates Market Forecast, By Application Type 13.19.1. Blood Cancer 13.19.2. Prostate cancer 13.19.3. kidney cancer 13.19.4. Pancreas cancer 13.19.5. Ovary cancer 13.19.6. lung cancer 13.19.7. Colon cancer 13.19.8. Breast cancer 13.19.9. Skin cancer 13.19.10. Other cancers 13.20. U.S. Antibody Drug Conjugates Market Forecast, By End User 13.20.1. Hospitals 13.20.2. Specialized cancer centers 13.20.3. Academic research institutes 13.20.4. Biotechnology companies 13.20.5. Biopharmaceutical companies 13.20.6. others 13.21. Canada Antibody Drug Conjugates Market Forecast, By Product types 13.21.1. Adcertis 13.21.2. Kadcyla 13.21.3. others 13.22. Canada Antibody Drug Conjugates Market Forecast, By Technology Type 13.22.1. ImmunoGen technology 13.22.2. Seattle Genetics technology 13.22.3. Immunomedics technology 13.22.4. others 13.23. Canada Antibody Drug Conjugates Market Forecast, By Type 13.23.1. Monoclonal antibodies 13.23.2. linker 13.23.3. drug/toxin 13.23.4. others 13.24. Canada Transplantation Market Forecast, By Application Type 13.24.1. Blood Cancer 13.24.2. Prostate cancer 13.24.3. kidney cancer 13.24.4. Pancreas cancer 13.24.5. Ovary cancer 13.24.6. lung cancer 13.24.7. Colon cancer 13.24.8. Breast cancer 13.24.9. Skin cancer 13.24.10. Other cancers 13.25. Canada Transplantation Market Forecast, By End User 13.25.1. Hospitals 13.25.2. Specialized cancer centers 13.25.3. Academic research institutes 13.25.4. Biotechnology companies 13.25.5. Biopharmaceutical companies 13.25.6. others 13.26. North America Antibody Drug Conjugates Market Attractiveness Analysis 13.26.1. By Product types 13.26.2. By Technology Type 13.26.3. By Type 13.26.4. By Application Type 13.26.5. By End User 13.27. PEST Analysis 13.28. Key Trends 13.29. Key Developments 14. Europe Antibody Drug Conjugates Market Analysis 14.1. Key Findings 14.2. Europe Antibody Drug Conjugates Market Overview 14.3. Europe Antibody Drug Conjugates Market Value Share Analysis, By Product types 14.4. Europe Antibody Drug Conjugates Market Forecast, By Product types 14.4.1. Adcertis 14.4.2. Kadcyla 14.4.3. others 14.5. Europe Antibody Drug Conjugates Market Value Share Analysis, By Technology Type 14.6. Europe Antibody Drug Conjugates Market Forecast, By Technology Type 14.6.1. ImmunoGen technology 14.6.2. Seattle Genetics technology 14.6.3. Immunomedics technology 14.6.4. others 14.7. Europe Antibody Drug Conjugates Market Value Share Analysis, By Type 14.8. Europe Antibody Drug Conjugates Market Forecast, By Type 14.8.1. Monoclonal antibodies 14.8.2. linker 14.8.3. drug/toxin 14.8.4. others 14.9. Europe Antibody Drug Conjugates Market Value Share Analysis, By Application Type 14.10. Europe Antibody Drug Conjugates Market Forecast, By Application Type 14.10.1. Blood Cancer 14.10.2. Prostate cancer 14.10.3. kidney cancer 14.10.4. Pancreas cancer 14.10.5. Ovary cancer 14.10.6. lung cancer 14.10.7. Colon cancer 14.10.8. Breast cancer 14.10.9. Skin cancer 14.10.10. Other cancers 14.11. Europe Antibody Drug Conjugates Market Value Share Analysis, By End User 14.12. Europe Antibody Drug Conjugates Market Forecast, By End User 14.12.1. Hospitals 14.12.2. Specialized cancer centers 14.12.3. Academic research institutes 14.12.4. Biotechnology companies 14.12.5. Biopharmaceutical companies 14.12.6. others 14.13. Europe Antibody Drug Conjugates Market Value Share Analysis, by Country 14.14. Europe Antibody Drug Conjugates Market Forecast, by Country 14.14.1. Germany 14.14.2. U.K. 14.14.3. France 14.14.4. Italy 14.14.5. Spain 14.14.6. Rest of Europe 14.15. Europe Antibody Drug Conjugates Market Analysis, by Country 14.16. Germany Antibody Drug Conjugates Market Forecast, By Product types 14.16.1. Adcertis 14.16.2. Kadcyla 14.16.3. others 14.17. Germany Antibody Drug Conjugates Market Forecast, By Technology Type 14.17.1. ImmunoGen technology 14.17.2. Seattle Genetics technology 14.17.3. Immunomedics technology 14.17.4. others 14.18. Germany Antibody Drug Conjugates Market Forecast, By Type 14.18.1. Monoclonal antibodies 14.18.2. linker 14.18.3. drug/toxin 14.18.4. others 14.19. Germany Antibody Drug Conjugates Market Forecast, By Application Type 14.19.1. Blood Cancer 14.19.2. Prostate cancer 14.19.3. kidney cancer 14.19.4. Pancreas cancer 14.19.5. Ovary cancer 14.19.6. lung cancer 14.19.7. Colon cancer 14.19.8. Breast cancer 14.19.9. Skin cancer 14.19.10. Other cancers 14.20. GermanyAntibody Drug Conjugates Market Forecast, By End User 14.20.1. Hospitals 14.20.2. Specialized cancer centers 14.20.3. Academic research institutes 14.20.4. Biotechnology companies 14.20.5. Biopharmaceutical companies 14.20.6. others 14.21. U.K. Antibody Drug Conjugates Market Forecast, By Product types 14.21.1. Adcertis 14.21.2. Kadcyla 14.21.3. others 14.22. U.K. Antibody Drug Conjugates Market Forecast, By Technology Type 14.22.1. ImmunoGen technology 14.22.2. Seattle Genetics technology 14.22.3. Immunomedics technology 14.22.4. others 14.23. U.K. Antibody Drug Conjugates Market Forecast, By Type 14.23.1. Monoclonal antibodies 14.23.2. linker 14.23.3. drug/toxin 14.23.4. others 14.24. U.K. Antibody Drug Conjugates Market Forecast, By Application Type 14.24.1. Blood Cancer 14.24.2. Prostate cancer 14.24.3. kidney cancer 14.24.4. Pancreas cancer 14.24.5. Ovary cancer 14.24.6. lung cancer 14.24.7. Colon cancer 14.24.8. Breast cancer 14.24.9. Skin cancer 14.24.10. Other cancers 14.25. U.K. Antibody Drug Conjugates Market Forecast, By End User 14.25.1. Hospitals 14.25.2. Specialized cancer centers 14.25.3. Academic research institutes 14.25.4. Biotechnology companies 14.25.5. Biopharmaceutical companies 14.25.6. others 14.26. France Antibody Drug Conjugates Market Forecast, By Product types 14.26.1. Adcertis 14.26.2. Kadcyla 14.26.3. others 14.27. France Antibody Drug Conjugates Market Forecast, By Technology Type 14.27.1. ImmunoGen technology 14.27.2. Seattle Genetics technology 14.27.3. Immunomedics technology 14.27.4. others 14.28. France Antibody Drug Conjugates Market Forecast, By Type 14.28.1. Monoclonal antibodies 14.28.2. linker 14.28.3. drug/toxin 14.28.4. others 14.29. France Antibody Drug Conjugates Market Forecast, By Application Type 14.29.1. Blood Cancer 14.29.2. Prostate cancer 14.29.3. kidney cancer 14.29.4. Pancreas cancer 14.29.5. Ovary cancer 14.29.6. lung cancer 14.29.7. Colon cancer 14.29.8. Breast cancer 14.29.9. Skin cancer 14.29.10. Other cancers 14.30. France Antibody Drug Conjugates Market Forecast, By End User 14.30.1. Hospitals 14.30.2. Specialized cancer centers 14.30.3. Academic research institutes 14.30.4. Biotechnology companies 14.30.5. Biopharmaceutical companies 14.30.6. others 14.31. Italy Antibody Drug Conjugates Market Forecast, By Product types 14.31.1. Adcertis 14.31.2. Kadcyla 14.31.3. others 14.32. Italy Antibody Drug Conjugates Market Forecast, By Technology Type 14.32.1. ImmunoGen technology 14.32.2. Seattle Genetics technology 14.32.3. Immunomedics technology 14.32.4. others 14.33. Italy Antibody Drug Conjugates Market Forecast, By Type 14.33.1. Monoclonal antibodies 14.33.2. linker 14.33.3. drug/toxin 14.33.4. others 14.34. Italy Antibody Drug Conjugates Market Forecast, By Application Type 14.34.1. Blood Cancer 14.34.2. Prostate cancer 14.34.3. kidney cancer 14.34.4. Pancreas cancer 14.34.5. Ovary cancer 14.34.6. lung cancer 14.34.7. Colon cancer 14.34.8. Breast cancer 14.34.9. Skin cancer 14.34.10. Other cancers 14.35. Italy Antibody Drug Conjugates Market Forecast, By End User 14.35.1. Hospitals 14.35.2. Specialized cancer centers 14.35.3. Academic research institutes 14.35.4. Biotechnology companies 14.35.5. Biopharmaceutical companies 14.35.6. others 14.36. Spain Antibody Drug Conjugates Market Forecast, By Product types 14.36.1. Adcertis 14.36.2. Kadcyla 14.36.3. others 14.37. Spain Antibody Drug Conjugates Market Forecast, By Technology Type 14.37.1. ImmunoGen technology 14.37.2. Seattle Genetics technology 14.37.3. Immunomedics technology 14.37.4. others 14.38. Spain Antibody Drug Conjugates Market Forecast, By Type 14.38.1. Monoclonal antibodies 14.38.2. linker 14.38.3. drug/toxin 14.38.4. others 14.39. Spain Antibody Drug Conjugates Market Forecast, By Application Type 14.39.1. Blood Cancer 14.39.2. Prostate cancer 14.39.3. kidney cancer 14.39.4. Pancreas cancer 14.39.5. Ovary cancer 14.39.6. lung cancer 14.39.7. Colon cancer 14.39.8. Breast cancer 14.39.9. Skin cancer 14.39.10. Other cancers 14.40. Spain Antibody Drug Conjugates Market Forecast, By End User 14.40.1. Hospitals 14.40.2. Specialized cancer centers 14.40.3. Academic research institutes 14.40.4. Biotechnology companies 14.40.5. Biopharmaceutical companies 14.40.6. others 14.41. Rest of Europe Antibody Drug Conjugates Market Forecast, By Product types 14.41.1. Adcertis 14.41.2. Kadcyla 14.41.3. others 14.42. Rest of Europe Antibody Drug Conjugates Market Forecast, By Technology Type 14.42.1. ImmunoGen technology 14.42.2. Seattle Genetics technology 14.42.3. Immunomedics technology 14.42.4. others 14.43. Rest Of Europe Antibody Drug Conjugates Market Forecast, By Type 14.43.1. Monoclonal antibodies 14.43.2. linker 14.43.3. drug/toxin 14.43.4. others 14.44. Rest of Europe Antibody Drug Conjugates Market Forecast, By Application Type 14.44.1. Blood Cancer 14.44.2. Prostate cancer 14.44.3. kidney cancer 14.44.4. Pancreas cancer 14.44.5. Ovary cancer 14.44.6. lung cancer 14.44.7. Colon cancer 14.44.8. Breast cancer 14.44.9. Skin cancer 14.44.10. Other cancers 14.45. Rest of Europe. Antibody Drug Conjugates Market Forecast, By End User 14.45.1. Hospitals 14.45.2. Specialized cancer centers 14.45.3. Academic research institutes 14.45.4. Biotechnology companies 14.45.5. Biopharmaceutical companies 14.45.6. others 14.46. Europe Antibody Drug Conjugates Market Attractiveness Analysis 14.46.1. By Product types 14.46.2. By Technology Type 14.46.3. By Type 14.46.4. By Application Type 14.46.5. By End User 14.47. PEST Analysis 14.48. Key Trends 14.49. Key Developments 15. Asia Pacific Antibody Drug Conjugates Market Analysis 15.1. Key Findings 15.2. Asia Pacific Antibody Drug Conjugates Market Overview 15.3. Asia Pacific Antibody Drug Conjugates Market Value Share Analysis, By Product types 15.4. Asia Pacific Antibody Drug Conjugates Market Forecast, By Product types 15.4.1. Adcertis 15.4.2. Kadcyla 15.4.3. others 15.5. Asia Pacific Antibody Drug Conjugates Market Value Share Analysis, By Technology Type 15.6. Asia Pacific Antibody Drug Conjugates Market Forecast, By Technology Type 15.6.1. ImmunoGen technology 15.6.2. Seattle Genetics technology 15.6.3. Immunomedics technology 15.6.4. others 15.7. Asia Pacific Antibody Drug Conjugates Market Value Share Analysis, By Type 15.8. Asia Pacific Antibody Drug Conjugates Market Forecast, By Type 15.8.1. Monoclonal antibodies 15.8.2. linker 15.8.3. drug/toxin 15.8.4. others 15.9. Asia Pacific Antibody Drug Conjugates Market Value Share Analysis, By Application Type 15.10. North America Antibody Drug Conjugates Market Forecast, By Application Type 15.10.1. Blood Cancer 15.10.2. Prostate cancer 15.10.3. kidney cancer 15.10.4. Pancreas cancer 15.10.5. Ovary cancer 15.10.6. lung cancer 15.10.7. Colon cancer 15.10.8. Breast cancer 15.10.9. Skin cancer 15.10.10. Other cancers 15.11. Asia Pacific Antibody Drug Conjugates Market Value Share Analysis, By End User 15.12. North America Antibody Drug Conjugates Market Forecast, By End User 15.12.1. Hospitals 15.12.2. Specialized cancer centers 15.12.3. Academic research institutes 15.12.4. Biotechnology companies 15.12.5. Biopharmaceutical companies 15.12.6. others 15.13. Asia Pacific Antibody Drug Conjugates Market Value Share Analysis, by Country 15.14. Asia Pacific Antibody Drug Conjugates Market Forecast, by Country 15.14.1. China 15.14.2. India 15.14.3. Japan 15.14.4. ASEAN 15.14.5. Rest of Asia Pacific 15.15. Asia Pacific Antibody Drug Conjugates Market Analysis, by Country 15.16. China Antibody Drug Conjugates Market Forecast, By Product types 15.16.1. Adcertis 15.16.2. Kadcyla 15.16.3. others 15.17. China Antibody Drug Conjugates Market Forecast, By Technology Type 15.17.1. ImmunoGen technology 15.17.2. Seattle Genetics technology 15.17.3. Immunomedics technology 15.17.4. others 15.18. China Antibody Drug Conjugates Market Forecast, By Type 15.18.1. Monoclonal antibodies 15.18.2. linker 15.18.3. drug/toxin 15.18.4. others 15.19. China. Antibody Drug Conjugates Market Forecast, By Application Type 15.19.1. Blood Cancer 15.19.2. Prostate cancer 15.19.3. kidney cancer 15.19.4. Pancreas cancer 15.19.5. Ovary cancer 15.19.6. lung cancer 15.19.7. Colon cancer 15.19.8. Breast cancer 15.19.9. Skin cancer 15.19.10. Other cancers 15.20. China Antibody Drug Conjugates Market Forecast, By End User 15.20.1. Hospitals 15.20.2. Specialized cancer centers 15.20.3. Academic research institutes 15.20.4. Biotechnology companies 15.20.5. Biopharmaceutical companies 15.20.6. others 15.21. India Antibody Drug Conjugates Market Forecast, By Product types 15.21.1. Adcertis 15.21.2. Kadcyla 15.21.3. others 15.22. India Antibody Drug Conjugates Market Forecast, By Technology Type 15.22.1. ImmunoGen technology 15.22.2. Seattle Genetics technology 15.22.3. Immunomedics technology 15.22.4. others 15.23. India Antibody Drug Conjugates Market Forecast, By Type 15.23.1. Monoclonal antibodies 15.23.2. linker 15.23.3. drug/toxin 15.23.4. others 15.24. India Antibody Drug Conjugates Market Forecast, By Application Type 15.24.1. Blood Cancer 15.24.2. Prostate cancer 15.24.3. kidney cancer 15.24.4. Pancreas cancer 15.24.5. Ovary cancer 15.24.6. lung cancer 15.24.7. Colon cancer 15.24.8. Breast cancer 15.24.9. Skin cancer 15.24.10. Other cancers 15.25. India Antibody Drug Conjugates Market Forecast, By End User 15.25.1. Hospitals 15.25.2. Specialized cancer centers 15.25.3. Academic research institutes 15.25.4. Biotechnology companies 15.25.5. Biopharmaceutical companies 15.25.6. others 15.26. Japan Antibody Drug Conjugates Market Forecast, By Product types 15.26.1. Adcertis 15.26.2. Kadcyla 15.26.3. others 15.27. Japan Antibody Drug Conjugates Market Forecast, By Technology Type 15.27.1. ImmunoGen technology 15.27.2. Seattle Genetics technology 15.27.3. Immunomedics technology 15.27.4. others 15.28. Japan Antibody Drug Conjugates Market Forecast, By Type 15.28.1. Monoclonal antibodies 15.28.2. linker 15.28.3. drug/toxin 15.28.4. others 15.29. Japan Antibody Drug Conjugates Market Forecast, By Application Type 15.29.1. Blood Cancer 15.29.2. Prostate cancer 15.29.3. kidney cancer 15.29.4. Pancreas cancer 15.29.5. Ovary cancer 15.29.6. lung cancer 15.29.7. Colon cancer 15.29.8. Breast cancer 15.29.9. Skin cancer 15.29.10. Other cancers 15.30. Japan Antibody Drug Conjugates Market Forecast, By End User 15.30.1. Hospitals 15.30.2. Specialized cancer centers 15.30.3. Academic research institutes 15.30.4. Biotechnology companies 15.30.5. Biopharmaceutical companies 15.30.6. others 15.31. ASEAN Antibody Drug Conjugates Market Forecast, By Product types 15.31.1. Adcertis 15.31.2. Kadcyla 15.31.3. others 15.32. ASEAN Antibody Drug Conjugates Market Forecast, By Technology Type 15.32.1. ImmunoGen technology 15.32.2. Seattle Genetics technology 15.32.3. Immunomedics technology 15.32.4. others 15.33. ASEAN Antibody Drug Conjugates Market Forecast, By Type 15.33.1. Monoclonal antibodies 15.33.2. linker 15.33.3. drug/toxin 15.33.4. others 15.34. ASEAN Antibody Drug Conjugates Market Forecast, By Application Type 15.34.1. Blood Cancer 15.34.2. Prostate cancer 15.34.3. kidney cancer 15.34.4. Pancreas cancer 15.34.5. Ovary cancer 15.34.6. lung cancer 15.34.7. Colon cancer 15.34.8. Breast cancer 15.34.9. Skin cancer 15.34.10. Other cancers 15.35. ASEAN Antibody Drug Conjugates Market Forecast, By End User 15.35.1. Hospitals 15.35.2. Specialized cancer centers 15.35.3. Academic research institutes 15.35.4. Biotechnology companies 15.35.5. Biopharmaceutical companies 15.35.6. others 15.36. Rest of Asia Pacific Antibody Drug Conjugates Market Forecast, By Product types 15.36.1. Adcertis 15.36.2. Kadcyla 15.36.3. others 15.37. Rest of Asia Pacific Antibody Drug Conjugates Market Forecast, By Technology Type 15.37.1. ImmunoGen technology 15.37.2. Seattle Genetics technology 15.37.3. Immunomedics technology 15.37.4. others 15.38. Rest of Asia Pacific Antibody Drug Conjugates Market Forecast, By Type 15.38.1. Monoclonal antibodies 15.38.2. linker 15.38.3. drug/toxin 15.38.4. others 15.39. Rest of Asia Antibody Drug Conjugates Market Forecast, By Application Type 15.39.1. Blood Cancer 15.39.2. Prostate cancer 15.39.3. kidney cancer 15.39.4. Pancreas cancer 15.39.5. Ovary cancer 15.39.6. lung cancer 15.39.7. Colon cancer 15.39.8. Breast cancer 15.39.9. Skin cancer 15.39.10. Other cancers 15.40. Rest of Asia Antibody Drug Conjugates Market Forecast, By End User 15.40.1. Hospitals 15.40.2. Specialized cancer centers 15.40.3. Academic research institutes 15.40.4. Biotechnology companies 15.40.5. Biopharmaceutical companies 15.40.6. others 15.41. Asia Pacific Antibody Drug Conjugates Market Attractiveness Analysis 15.41.1. By Product types 15.41.2. By Technology Type 15.41.3. By Type 15.41.4. By Application Type 15.41.5. By End User 15.42. PEST Analysis 15.43. Key Trends 15.44. Key Developments 16. Middle East & Africa Antibody Drug Conjugates Market Analysis 16.1. Key Findings 16.2. Middle East & Africa Antibody Drug Conjugates Market Overview 16.3. Middle East & Africa Antibody Drug Conjugates Market Value Share Analysis, By Product types 16.4. Middle East & Africa Antibody Drug Conjugates Market Forecast, By Product types 16.4.1. Adcertis 16.4.2. Kadcyla 16.4.3. others 16.5. Middle East & Africa Antibody Drug Conjugates Market Value Share Analysis, By Technology Type 16.6. Middle East & Africa Antibody Drug Conjugates Market Forecast, By Technology Type 16.6.1. ImmunoGen technology 16.6.2. Seattle Genetics technology 16.6.3. Immunomedics technology 16.6.4. others 16.7. Middle East & Africa Antibody Drug Conjugates Market Value Share Analysis, By Type 16.8. Middle East & Africa Antibody Drug Conjugates Market Forecast, By Type 16.8.1. Monoclonal antibodies 16.8.2. linker 16.8.3. drug/toxin 16.8.4. others 16.9. Middle East & Africa Antibody Drug Conjugates Market Value Share Analysis, By Application Type 16.10. North America Antibody Drug Conjugates Market Forecast, By Application Type 16.10.1. Blood Cancer 16.10.2. Prostate cancer 16.10.3. kidney cancer 16.10.4. Pancreas cancer 16.10.5. Ovary cancer 16.10.6. lung cancer 16.10.7. Colon cancer 16.10.8. Breast cancer 16.10.9. Skin cancer 16.10.10. Other cancers 16.11. Middle East & Africa North America Antibody Drug Conjugates Market Value Share Analysis, By End User 16.12. North America Antibody Drug Conjugates Market Forecast, By End User 16.12.1. Hospitals 16.12.2. Specialized cancer centers 16.12.3. Academic research institutes 16.12.4. Biotechnology companies 16.12.5. Biopharmaceutical companies 16.12.6. others 16.13. Middle East & Africa Antibody Drug Conjugates Market Value Share Analysis, by Country 16.14. Middle East & Africa Antibody Drug Conjugates Market Forecast, by Country 16.14.1. GCC 16.14.2. South Africa 16.14.3. Rest of Middle East & Africa 16.15. Middle East & Africa Antibody Drug Conjugates Market Analysis, by Country 16.16. GCC Antibody Drug Conjugates Market Forecast, By Product types 16.16.1. Adcertis 16.16.2. Kadcyla 16.16.3. others 16.17. GCC Antibody Drug Conjugates Market Forecast, By Technology Type 16.17.1. ImmunoGen technology 16.17.2. Seattle Genetics technology 16.17.3. Immunomedics technology 16.17.4. others 16.18. GCC Antibody Drug Conjugates Market Forecast, By Type 16.18.1. Monoclonal antibodies 16.18.2. linker 16.18.3. drug/toxin 16.18.4. others 16.19. GCC U.S. Antibody Drug Conjugates Market Forecast, By Application Type 16.19.1. Blood Cancer 16.19.2. Prostate cancer 16.19.3. kidney cancer 16.19.4. Pancreas cancer 16.19.5. Ovary cancer 16.19.6. lung cancer 16.19.7. Colon cancer 16.19.8. Breast cancer 16.19.9. Skin cancer 16.19.10. Other cancers 16.20. GCC Antibody Drug Conjugates Market Forecast, By End User 16.20.1. Hospitals 16.20.2. Specialized cancer centers 16.20.3. Academic research institutes 16.20.4. Biotechnology companies 16.20.5. Biopharmaceutical companies 16.20.6. others 16.21. South Africa Antibody Drug Conjugates Market Forecast, By Product types 16.21.1. Adcertis 16.21.2. Kadcyla 16.21.3. others 16.22. South Africa Antibody Drug Conjugates Market Forecast, By Technology Type 16.22.1. ImmunoGen technology 16.22.2. Seattle Genetics technology 16.22.3. Immunomedics technology 16.22.4. others 16.23. South Africa Antibody Drug Conjugates Market Forecast, By Type 16.23.1. Monoclonal antibodies 16.23.2. linker 16.23.3. drug/toxin 16.23.4. others 16.24. South Africa Antibody Drug Conjugates Market Forecast, By Application Type 16.24.1. Blood Cancer 16.24.2. Prostate cancer 16.24.3. kidney cancer 16.24.4. Pancreas cancer 16.24.5. Ovary cancer 16.24.6. lung cancer 16.24.7. Colon cancer 16.24.8. Breast cancer 16.24.9. Skin cancer 16.24.10. Other cancers 16.25. South Africa U.S. Antibody Drug Conjugates Market Forecast, By End User 16.25.1. Hospitals 16.25.2. Specialized cancer centers 16.25.3. Academic research institutes 16.25.4. Biotechnology companies 16.25.5. Biopharmaceutical companies 16.25.6. others 16.26. Rest of Middle East & Africa Antibody Drug Conjugates Market Forecast, By Product types 16.26.1. Adcertis 16.26.2. Kadcyla 16.26.3. others 16.27. Rest of Middle East & Africa Antibody Drug Conjugates Market Forecast, By Technology Type 16.27.1. ImmunoGen technology 16.27.2. Seattle Genetics technology 16.27.3. Immunomedics technology 16.27.4. others 16.28. Middle East & Africa Antibody Drug Conjugates Market Forecast, By Type 16.28.1. Monoclonal antibodies 16.28.2. linker 16.28.3. drug/toxin 16.28.4. others 16.29. Rest of Middle East & Africa Antibody Drug Conjugates Market Forecast, By Application Type 16.29.1. Blood Cancer 16.29.2. Prostate cancer 16.29.3. kidney cancer 16.29.4. Pancreas cancer 16.29.5. Ovary cancer 16.29.6. lung cancer 16.29.7. Colon cancer 16.29.8. Breast cancer 16.29.9. Skin cancer 16.29.10. Other cancers 16.30. Rest of Middle East & Africa Antibody Drug Conjugates Market Forecast, By End User 16.30.1. Hospitals 16.30.2. Specialized cancer centers 16.30.3. Academic research institutes 16.30.4. Biotechnology companies 16.30.5. Biopharmaceutical companies 16.30.6. others 16.31. Middle East & Africa Antibody Drug Conjugates Market Attractiveness Analysis 16.31.1. By Product types 16.31.2. By Technology Type 16.31.3. By Type 16.31.4. By Application Type 16.31.5. By End User 16.32. PEST Analysis 16.33. Key Trends 16.34. Key Developments 17. South America Antibody Drug Conjugates Market Analysis 17.1. Key Findings 17.2. South America Antibody Drug Conjugates Market Overview 17.3. South America Antibody Drug Conjugates Market Value Share Analysis, By Product types 17.4. South America Antibody Drug Conjugates Market Forecast, By Product types 17.4.1. Adcertis 17.4.2. Kadcyla 17.4.3. others 17.5. South America Antibody Drug Conjugates Market Value Share Analysis, By Technology Type 17.6. South America Antibody Drug Conjugates Market Forecast, By Technology Type 17.6.1. ImmunoGen technology 17.6.2. Seattle Genetics technology 17.6.3. Immunomedics technology 17.6.4. others 17.7. South America Antibody Drug Conjugates Market Value Share Analysis, By Type 17.8. South America Antibody Drug Conjugates Market Forecast, By Type 17.8.1. Monoclonal antibodies 17.8.2. linker 17.8.3. drug/toxin 17.8.4. others 17.9. South America Antibody Drug Conjugates Market Value Share Analysis, By Application Type 17.10. South America Antibody Drug Conjugates Market Forecast, By Application Type 17.10.1. Blood Cancer 17.10.2. Prostate cancer 17.10.3. kidney cancer 17.10.4. Pancreas cancer 17.10.5. Ovary cancer 17.10.6. lung cancer 17.10.7. Colon cancer 17.10.8. Breast cancer 17.10.9. Skin cancer 17.10.10. Other cancers 17.11. South America Antibody Drug Conjugates Market Value Share Analysis, By End User 17.12. South America Antibody Drug Conjugates Market Forecast, By End User 17.12.1. Hospitals 17.12.2. Specialized cancer centers 17.12.3. Academic research institutes 17.12.4. Biotechnology companies 17.12.5. Biopharmaceutical companies 17.12.6. others 17.13. South America Antibody Drug Conjugates Market Value Share Analysis, by Country 17.14. South America Antibody Drug Conjugates Market Forecast, by Country 17.14.1. Brazil 17.14.2. Mexico 17.14.3. Rest of South America 17.15. South America Antibody Drug Conjugates Market Analysis, by Country 17.16. Brazil Antibody Drug Conjugates Market Forecast, By Product types 17.16.1. Adcertis 17.16.2. Kadcyla 17.16.3. others 17.17. Brazil Antibody Drug Conjugates Market Forecast, By Technology Type 17.17.1. ImmunoGen technology 17.17.2. Seattle Genetics technology 17.17.3. Immunomedics technology 17.17.4. others 17.18. Brazil Antibody Drug Conjugates Market Forecast, By Type 17.18.1. Monoclonal antibodies 17.18.2. linker 17.18.3. drug/toxin 17.18.4. others 17.19. Brazil Antibody Drug Conjugates Market Forecast, By Application Type 17.19.1. Blood Cancer 17.19.2. Prostate cancer 17.19.3. kidney cancer 17.19.4. Pancreas cancer 17.19.5. Ovary cancer 17.19.6. lung cancer 17.19.7. Colon cancer 17.19.8. Breast cancer 17.19.9. Skin cancer 17.19.10. Other cancers 17.20. Brazil. Antibody Drug Conjugates Market Forecast, By End User 17.20.1. Hospitals 17.20.2. Specialized cancer centers 17.20.3. Academic research institutes 17.20.4. Biotechnology companies 17.20.5. Biopharmaceutical companies 17.20.6. others 17.21. Mexico Antibody Drug Conjugates Market Forecast, By Product types 17.21.1. Adcertis 17.21.2. Kadcyla 17.21.3. others 17.22. Mexico Antibody Drug Conjugates Market Forecast, By Technology Type 17.22.1. ImmunoGen technology 17.22.2. Seattle Genetics technology 17.22.3. Immunomedics technology 17.22.4. others 17.23. Mexico Antibody Drug Conjugates Market Forecast, By Type 17.23.1. Monoclonal antibodies 17.23.2. linker 17.23.3. drug/toxin 17.23.4. others 17.24. Mexico Antibody Drug Conjugates Market Forecast, By Application Type 17.24.1. Blood Cancer 17.24.2. Prostate cancer 17.24.3. kidney cancer 17.24.4. Pancreas cancer 17.24.5. Ovary cancer 17.24.6. lung cancer 17.24.7. Colon cancer 17.24.8. Breast cancer 17.24.9. Skin cancer 17.24.10. Other cancers 17.25. Mexico Antibody Drug Conjugates Market Forecast, By End User 17.25.1. Hospitals 17.25.2. Specialized cancer centers 17.25.3. Academic research institutes 17.25.4. Biotechnology companies 17.25.5. Biopharmaceutical companies 17.25.6. others 17.26. Rest of South America Antibody Drug Conjugates Market Forecast, By Product types 17.26.1. Adcertis 17.26.2. Kadcyla 17.26.3. others 17.27. Rest of South America Antibody Drug Conjugates Market Forecast, By Technology Type 17.27.1. ImmunoGen technology 17.27.2. Seattle Genetics technology 17.27.3. Immunomedics technology 17.27.4. others 17.28. Rest of South America Antibody Drug Conjugates Market Forecast, By Type 17.28.1. Monoclonal antibodies 17.28.2. linker 17.28.3. drug/toxin 17.28.4. others 17.29. Rest of South America Antibody Drug Conjugates Market Forecast, By Application Type 17.29.1. Blood Cancer 17.29.2. Prostate cancer 17.29.3. kidney cancer 17.29.4. Pancreas cancer 17.29.5. Ovary cancer 17.29.6. lung cancer 17.29.7. Colon cancer 17.29.8. Breast cancer 17.29.9. Skin cancer 17.29.10. Other cancers 17.30. Rest of South America Antibody Drug Conjugates Market Forecast, By End User 17.30.1. Hospitals 17.30.2. Specialized cancer centers 17.30.3. Academic research institutes 17.30.4. Biotechnology companies 17.30.5. Biopharmaceutical companies 17.30.6. others 17.31. South America Antibody Drug Conjugates Market Attractiveness Analysis 17.31.1. By Product types 17.31.2. By Technology Type 17.31.3. By Type 17.31.4. By Application Type 17.31.5. By End User 17.32. PEST Analysis 17.33. Key Trends 17.34. Key Developments 18. Company Profiles 18.1. Market Share Analysis, by Company 18.2. Competition Matrix 18.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 18.2.2. New Product Launches and Product Enhancements 18.2.3. Market Consolidation 18.2.3.1. M&A by Regions, Investment and Applications 18.2.3.2. M&A Key Players, Forward Integration and Backward 18.2.3.3. Integration 18.3. Company Profiles: Key Players 18.3.1. Novartis 18.3.1.1. Company Overview 18.3.1.2. Financial Overview 18.3.1.3. Product Portfolio 18.3.1.4. Business Strategy 18.3.1.5. Recent Developments 18.3.1.6. Development Footprint 18.3.2. Merck 18.3.3. Roche 18.3.4. AbbVie 18.3.5. UCB 18.3.6. Bristol-Myers Squibb 18.3.7. Stem CentRx 18.3.8. Biogen Idec 18.3.9. Nordic Nanovector 18.3.10. Millennium 18.3.11. Biotest AG 18.3.12. PDL BioPharma 18.3.13. Progenics Pharmaceuticals 18.3.14. Seattle Genetics 18.3.15. Viventia Biotechnologies 18.3.16. AbGenomics Corporation 18.3.17. Helix BioPharma 18.3.18. ImmunoGen, Inc 18.3.19. Antikor 18.3.20. Pfizer Inc 18.3.21. Celldex Therapeutics 18.3.22. F. Hoffman-La Roche 18.3.23. Synthon Holding B.V. 18.3.24. Sanofi S.A. 18.3.25. Pfizer Inc. 18.3.26. Immunomedics Inc. 18.3.27. Bayer Healthcare Pharmaceuticals 18.3.28. Celldex Therapeutics Inc 19. Primary Key Insights